Interpace Biosciences®, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

STOCK-BASED COMPENSATION

STOCK-BASED COMPENSATION

6 Months Ended

Jun. 30, 2023

Share-Based Payment Arrangement [Abstract]

11. STOCK-BASED COMPENSATION

Historically, stock options have been granted with an exercise price equal to the market value of the common stock on the date of grant, with expiration 10 years from the date they are granted, and generally vest over a one to three-year period for employees and members of the Board. Upon exercise, new shares will be issued by the Company. The restricted shares and restricted stock units (“RSUs”) granted to Board members and employees generally have a three-year graded vesting period and are subject to accelerated vesting and forfeiture under certain circumstances.

There were no stock option awards issued during the six months ended June 30, 2023. The following table provides the weighted average assumptions used in determining the fair value of the stock option awards granted during the six-month period ended June 30, 2022.

	June 30, 2022

Risk-free interest rate		1.75	%
Expected life		6.0 years
Expected volatility		129.93	%
Dividend yield		-

The Company recognized approximately $0.2 million and $0.3 million of stock-based compensation expense within continuing operations during the three-month periods ended June 30, 2023 and 2022, respectively and approximately $0.3 million and $0.6 million for the six-month periods ended June 30, 2023 and 2022, respectively. The following table has a breakout of stock-based compensation expense from continuing operations by line item.

	2023		2022		2023		2022
	Three Months Ended				Six Months Ended
	June 30,				June 30,
	2023		2022		2023		2022

Cost of revenue	$	12	$	20	$	26	$	47
Sales and marketing		30		42		60		86
General and administrative*		115		243		263		475
Total stock compensation expense	$	157	$	305	$	349	$	608

*	Includes ESPP expense in 2022